UK Stocks-Factors to watch on March 2

March 1 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening open 28 points lower at 6,560 on Tuesday, according to financial bookmakers, with futures .FFIc1 down 0.08% ahead of the cash market open.

* TRAVIS PERKINS: Travis Perkins TPK.L , Britain's biggest seller of building materials, has recommenced the process to demerge its Wickes home improvement business, it said on Tuesday.

* LOOKERS: Lookers Plc LOOK.L said on Tuesday that the Financial Conduct Authority has closed its investigation into possible mis-selling of products by the motor retailer.

* ROBERT WALTERS: Robert Walters Plc RWA.L said on Tuesday its annual profit slumped 75% as the COVID-19 pandemic continued to affect hiring globally, even as the British recruiter saw signs of recovery in the job market in the last few months of 2020.

* WIZZ AIR: Passenger numbers at Wizz Air WIZZ.L plunged 87% in February compared to the same month last year, as the pandemic's impact on travel worsened again.

* FRESNILLO: Precious metals miner Fresnillo Plc FRES.L reported a sharp jump in full-year pre-tax profit on Tuesday, boosted by strong gold and silver prices, but the company said it remains cautious for 2021 due to the continued impact of the pandemic in Mexico.

* TAYLOR WIMPEY: Britain's third-largest homebuilder Taylor Wimpey TW.L said the 2021 selling season has started well, ahead of possible additional incentives for the sector in the budget, and resumed dividend payment as promised.

* MAN GROUP: British hedge fund manager Man Group EMG.L on Tuesday posted a slide in its 2020 core pretax profit, but raised its total dividend by 8% as funds under management touched a record high.

* CRODA: Specialty chemical company Croda CRDA.L said on Tuesday that it expects its deal to supply additives for Pfizer's COVID-19 vaccine to help support growth in its life sciences business, after reporting a drop in 2020 profit.

* RENISHAW: Engineering firm Renishaw Plc RSW.L said on Tuesday it was seeking a buyer for itself after the company's founders said they intended to sell their majority stake in the company.

* ASTRAZENECA: People in France aged over 65 with existing health problems can be given the AstraZeneca AZN.L COVID-19 vaccine, France's health minister said on Monday, departing from Paris's earlier stance that the vaccine should be for under-65s only.

* ASTRAZENECA: Canada's National Advisory Committee on Immunization released new guidelines on Monday that advise against vaccinating people who are 65 years and older with AstraZeneca's COVID-19 vaccine, citing lack of information about efficacy in that age group.

* BREXIT: The shift in financial staff and assets from the City of London to the European Union because of Brexit has eased after Britain completed its full departure from the bloc, a tracker from consultants EY showed.

* TAXES: British Prime Minister Boris Johnson has vowed in an interview with the Sun newspaper that his green agenda will not lead to any new tax rises.

* VACCINES: The Pfizer PFE.N and AstraZeneca vaccines are more than 80% effective at preventing hospitalisations from COVID-19 in those over 80 after one dose of either shot, Public Health England said on Monday, citing a pre-print study.

* REGULATOR: Britain's financial watchdog must act faster on scams, its chair said on Monday.

* GOLD: Gold prices slumped to their lowest in 8-1/2 months, as a stronger dollar and elevated U.S. Treasury yields eroded investor appetite for the non-yielding metal.

* OIL: Oil prices fell more than 1%, extending losses that began last week, as investors unwound long positions on concern that OPEC may agree to increase global supply in a meeting this week and Chinese demand may be slipping.

* British shares rose on Monday, led by homebuilders and miners on reports of more domestic fiscal support.

* For more on the factors affecting European stocks, please click on:


> Financial Times

> Other business headlines

Reporting by Shanima A and Tanishaa Nadkar in Bengaluru

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.